ClinicalTrials.gg
CompletedNCT07213063Updated Oct 30, 2026

Effects of Chronic Creatine and Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Oxidative Stress, Inflammation, Muscle Strength, and Body Composition in Individuals With Down Syndrome

An interventional study of Nutrition education and Supplement in Down Syndrome (DS) and Supplementation, sponsored by Universidad de Burgos. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Universidad de Burgos · Not applicable, Interventional, and Prevention

How we know

Updated Oct 30, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Down Syndrome with a site in Spain — 9 open to participants now, 9 under way, 1 of them phase 3. Down Syndrome · Spain.

Enrollment
13th of 18
32 · median 58
Started
2025
with 3 others
No phase
10 of 36
2 open now
Registered
32nd of 36
by date

Among the 36 studies in Down Syndrome with a site in Spain, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 with no phase, and was the 32nd registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

9 of the 36 studies in Down Syndrome with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Down Syndrome with a site in Spain, or all of them as a file.
02

Study summary

Purpose:

This study will test whether 8 weeks of creatine and HMB supplementation can improve muscle strength, body composition, balance, and overall health in people with Down syndrome. Participants will also receive nutrition tips during the study.

Who can participate:

People with Down syndrome who can perform basic physical tasks. Must provide consent from the participant and legal guardian.

What participants will do:

Take creatine (3 g/day) and HMB (3 g/day) or placebo for 8 weeks. Complete tests for muscle strength, balance, and cognitive function. Undergo body composition scans and give blood samples for health markers.

Timing:

All tests and blood samples are taken before and after each 8-week period.

Importance:

Results will help determine if creatine and HMB can safely improve strength, balance, and overall health in people with Down syndrome.

Read the detailed description

This study is an 8-week randomized, placebo-controlled, crossover trial designed to evaluate the effects of daily supplementation with creatine monohydrate (3 g) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g) on body composition, muscle strength, balance, cognitive function, and biomarkers of oxidative stress and inflammation in individuals with Down syndrome. Participants will receive nutritional education throughout the intervention to support a balanced diet.

Primary outcomes include lean mass measured by dual-energy X-ray absorptiometry (DXA).

Secondary outcomes include fat-free mass (bioimpedance), bone mineral density (DXA), handgrip strength, lower limb strength (Five Times Sit-to-Stand Test), upper and lower body isometric strength (K-Pull test), balance (4-Stage Balance Test), and cognitive function assessed by the Timed Up and Go Dual Task. Blood biomarkers of oxidative stress and inflammation, including reduced glutathione (GSH), superoxide dismutase (SOD), C-reactive protein (CRP), interleukins (IL-1, IL-6, IL-7), and tumor necrosis factor-alpha (TNF-α), will be assessed before and after each supplementation period.

All assessments will be performed at baseline and at the end of each 8-week supplementation phase, allowing for evaluation of both physiological and functional responses to creatine and HMB supplementation in this population.

03

Conditions studied

  • Down Syndrome (DS)
  • Supplementation

Browse trials for

Keywords

  • creatine
  • down syndrome
  • bone mineral health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis: Medical confirmation of Down syndrome (trisomy of chromosome 21).
  • Physical capacity: Ability to perform basic physical tests (e.g., standing up from a chair or walking without assistance).
  • : Informed consent will be obtained from both the participant and their legal representative, in compliance with current legislation for individuals requiring support measures.

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney disease: Diagnosis of chronic kidney disease.
  • Severe motor limitations: Inability to perform the required physical tests (e.g., paralysis or mobility impairments preventing the execution of muscle strength assessments).
  • Participation in other studies: Participation in another nutritional or supplementation intervention study within the last 6 months.
  • Allergies or intolerances: Known allergy to creatine or to components of the placebo (inulin).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Placebo

    Participants will receive placebo supplementation

    Other: Nutrition education · Dietary Supplement: Placebo

  • Experimental
    Supplementation

    Participants will receive creatine monohydrate and beta-hydroxy-beta-methylbutyrate supplementation

    Other: Nutrition education · Dietary Supplement: Supplement

Interventions

  • OtherNutrition education

    Participants and their families will also take part in nutrition education sessions to promote healthy eating and lifestyle habits.

  • Dietary supplementSupplement

    Supplementation with 3 g/day of creatine monohydrate abd 3 g/day of beta-hydroxy-beta-methylbutyrate for 8 weeks

  • Dietary supplementPlacebo

    Supplementation with 6 g/day of inulin orally for 8 weeks

06

What researchers measure

Primary outcomes

  1. Lean mass

    Lean mass (kg) will be evaluated using dual-energy X-ray absorptiometry (DXA): GE Lunar Prodigy DXA device (GE Healthcare, Madison, WI, USA; Encore software version).

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

Secondary outcomes

  1. Handgrip strength

    Handgrip strength (kg) will be assessed using a handgrip dynamometer.

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  2. Bone mineral density

    Total bone mineral density (g/cm2) will be evaluated using dual-energy X-ray absorptiometry (DXA): GE Lunar Prodigy DXA device (GE Healthcare, Madison, WI, USA; Encore software version).

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  3. Reduced glutathione (GSH).

    Blood samples will be collected to assess levels of reduced glutathione (GSH).

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  4. C-reactive protein (CRP)

    Blood samples will be collected to assess levels of inflammation including C-reactive protein (CRP).

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  5. Superoxide dismutase (SOD) activity.

    Blood samples will be collected to assess levels of superoxide dismutase (SOD) activity.

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  6. Blood levels of interleukins (IL-1, IL-6, IL-7).

    Blood samples will be collected to assess levels of interleukins (IL-1, IL-6, IL-7).

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  7. Tumor necrosis factor-alpha (TNF-α).

    Blood samples will be collected to assess levels of tumor necrosis factor-alpha (TNF-α).

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  8. Fat-free mass

    Fat free mass (kg) will be analysed using bioimpedance: InBody S10.

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  9. Lower limb strength

    Lower limb strength will be assessed using the Five Times Sit-to-Stand Test (5xSTS), which involved recording the time taken to rise from a 45 cm highchair five times as quickly as possible without using the arms for support.

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  10. Balance

    Balance will be using the 4-Stage Balance Test. It involves holding four progressively difficult positions for at least 10 seconds each: Feet together: 1 point if the position is held for 10 seconds or more. Partial semi-tandem: 1 point if the position is held for 10 seconds or more. Semi-tandem: * 2 points: If the position is held for more than 10 seconds. * 1 point: If the position is held for between 3 and 9.99 seconds. * 0 points: If the position is held for less than 3 seconds. The score ranges from 0 to 4 (best balance).

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  11. Cognitive function

    Cognitive function will be assessed with Timed Up and Go Dual Task (TUGdt) test. The participant first performs the Timed Up and Go (TUG) test alone, standing up from a chair, walking a short distance (3 meters) turning, and sitting back down, while simultaneously naming animals within a 10-second period, which assesses verbal fluency. The time taken to complete these distances will be recorded, and the fluency in naming the animals will be assessed.

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  12. Isometric lower body strength

    The K-Pull test will be used to evaluate isometric lower body strength Participants will perform a seated knee extension test, pushing their leg against the dynamometer with maximal effort. Participants will exert their maximum force against the unyielding device for 3-5 seconds. The peak force achieved (in Newtons) over a minimum of two trials will be recorded

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

  13. Isometric upper body strength

    The K-Pull test will be used to evaluate isometric upper body strength Participants will stand with their back against a wall to stabilize the torso. The participant will be instructed to exert a maximal force by pushing their arm outward against the device for 3-5 seconds.The peak force achieved (in Newtons or kilograms-force) over a minimum of two trials will be recorded.

    Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)

07

Study locations

1 site
  • Universidad de Burgos
    Burgos, Burgos 09003, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Apr 2026, 7 months.

Of 163 non-industry interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 33. This study's 7 months is below that.

Counting every sponsor, half of 165 studies reached it within 11 months; a quarter within 3 and three quarters within 35.

Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 8, 2025
StartActual
Sep 15, 2025
Primary completionActual
Apr 30, 2026
CompletionActual
Apr 30, 2026was May 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 30, 2026
Study completion
May 30, 2026→Apr 30, 2026 (actual)
Oct 30, 2026
Enrollment
50 (estimated)→32 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Recruiting→Completed
    Study completion May 30, 2026→Apr 30, 2026 (now actual)
    Enrollment 50 (estimated)→32 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07213063
Lead sponsor
Universidad de Burgos
Collaborators
European University Miguel de Cervantes
Responsible party
MARIA MARTINEZ (Principal Investigator, Universidad de Burgos) — Principal investigator
First posted
Oct 8, 2025
Start date
Sep 15, 2025
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion